Management of Hypertension and Dyslipidaemia in Patients Presenting with Hyperuricaemia: Case Histories

References

• Cannon, P. J., Stason, W. B., Demartini, F. E., Sommers S. C. and Laragh, J. H. (1966). Hyperuricemia in primary and renal hypertension. N. Engl. J. Med., 275, 457–464.
   PubMed Web of Science ®Google Scholar
• Breckenridge, A. (1966). Hypertension and hyperuricaemia. Lancet, 1, 15–18.
   PubMed Web of Science ®Google Scholar
• Ward, H. J. (1998). Uric acid as an independent risk factor in the treatment of hypertension. Lancet, 352, 670–671.
   PubMed Web of Science ®Google Scholar
• Langford, H. G., Blufox, M. D., Borhani, N. O., Curb, J. D., Molteni, A., Schneider, K. A. and Pressel, S. (1987). Is thiazide-produced uric acid elevation harmful? Analysis of data form the hypertension detection and follow-up program. Arch. Intern. Med., 147, 645–649.
   PubMed Web of Science ®Google Scholar
• Boona, K. H. and TheIle, D. S. (1991). Association between BP and serum lipids in a population: the Thompson study. Circulation, 83, 1305–1314.
   PubMed Web of Science ®Google Scholar
• Goode, G. K., Miller, J. P. and Heagerty, A. M. (1995). Hyperlipidemia, hypertension, and coronary artery disease. Lancet, 345, 362–364.
   PubMed Web of Science ®Google Scholar
• Giacomello, A., Di Sciascio, N. and Pio Quaratino, C. (1997). Relation between serum triglyceride level, serum urate concentration and fractional urate excretion. Metabolism, 46, 1085–1089.
   PubMed Web of Science ®Google Scholar
• Fox, I. H., John, D., DeBruyne, S., Dwosh, I. and Marliss, E. B. (1985). Hyperuricemia and hypertrigyceridemia: metabolic basis for the association. Metabolism, 34, 741–746.
   PubMed Web of Science ®Google Scholar
• Facchini, F., Ida Chen, Y.-D., Hollenbeck, C. B. and Reaven, G. M. (1991). Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concen-tration. J. Am. Med. Assoc., 266, 3008–3011.
   PubMed Web of Science ®Google Scholar
• Bradlow, A. (1997). Adverse reactions profile: allopurinol. Prescribers J., 27, 29–33.
   Google Scholar
• Campion, E. W., Glynn, R. J. and DeLabry, L. O. (1987). Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. Am. J. Med., 82, 421–426.
   PubMedGoogle Scholar
• Nakashima, M., Uematsu, T., Kosuge, K. and Kanamaru, M. (1992). Pilot study of the uricosuric effect of DuP-753: a new angiotensin II receptor antagonist, in healthy subjects. Eur. J. Clin. Pharmacol., 42, 333–335.
   PubMed Web of Science ®Google Scholar
• Shahinfar, S., Simpson, R. L., Carides, A. D., Thyagarajan, B., Nakagawa, Y., Parks, J. H. and Coe, F. L. for the Losartan Uric Acid Study Group. (1999). Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int., 56, 1879–1885.
   PubMed Web of Science ®Google Scholar
• Elisaf, M., Tsimichodimos, V., Bairaktari, E. and Siamopoulos, K. C. (1999). Effect of micronised fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. J. Cardiovasc. Pharmacol., 34, 60–63.
   PubMed Web of Science ®Google Scholar
• Edwards, R. M., Trizna, W., Stack, E. J. and Weinstock, J. (1996). Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes. J. Pharmacol. Exp. Ther, 276, 125–129.
   PubMed Web of Science ®Google Scholar
• Finlayson, B. (1978). Physicochemical aspects of urolithiasis. Kidney Int., 13, 344–360.
   PubMed Web of Science ®Google Scholar
• Harter, J. G. (1988). Acute flank pain and hematuria: lessons from adverse drug reaction reporting. J. Clin. Pharmacol., 28, 560–565.
   PubMedGoogle Scholar
• Barreto-Chavez, M. L. and Mello-Aires, M. (1996). Effect of luminal angiotensin II and ANP on early and late cortical distal tubule HCO3- reabsorption. Am. J. Physiol., 271, F977–F984.
   PubMed Web of Science ®Google Scholar
• The Hypertension Detection and Follow-up Program Cooperative Research Group. (1985). Mortality findings for stepped-care and referred-care participants in the Hypertension Detection and Follow-up Program, stratified by other risk factors. Prey. Med., 14, 312–335.
   PubMed Web of Science ®Google Scholar
• Bengtsson, C., Lapidus, L., Stendahl, C. and Waldenstrom, J. (1988). Hyperuricemia and risk of cardiovascular disease and overall death: a 12-year follow up of participants in the population study of women in Gothenburg, Sweden. Acta Med. Scand., 224, 549–555.
   PubMed Web of Science ®Google Scholar
• Iribarren, C., Folsom, A. R., Eckfeldt, J. H., McGovern, P. G. and Nieto, F. J. (1996). Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC study. Ann. Epidemiol., 6, 331–340.
   PubMed Web of Science ®Google Scholar
• Yano, K., Reed, D. M. and McGee, D. L. (1984). Ten-year incidence of coronary heart disease in the Honolulu Heart Program: relationship to biologic and lifestyle characteristics. Am. J. Epidemiol., 119, 653–656.
   PubMed Web of Science ®Google Scholar
• Brand, F. N., McGee, D. L., Kannel, W. B., Stokes, J. and CasteIli, W. P. (1985). Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am. J. Epidemiol., 121, 11–18.
   PubMed Web of Science ®Google Scholar
• Freedman, D. S., Williamson, D. F., Gunter, E. W. and Byers, T. (1995). Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am. J. Epidemiol., 141, 637–644.
   PubMed Web of Science ®Google Scholar
• Kannel, W. B. (1985). Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am. Heart J., 114, 413–419.
   Web of Science ®Google Scholar
• Iribarren, C., Sharp, D. S., Curb, J. D. and Yano, K. (1996). High uric acid: a metabolic marker of coronary heart disease among alcohol abstainers? J. UM. Epidemiol., 49, 673–678.
   Web of Science ®Google Scholar
• Nieto, F. J., Iribaren, C., Gross, M. D., Comstock, G. W. and Cutler, R. G. (2280). Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis, 148, 131–139.
   Google Scholar
• Naknishi, N., Suzuki, K., Kawashimo, H., Nakamura, K. and Tatara, K. (1999). Serum uric acid: correlation with biological, clinical and behavioral factors in Japanese men. J. Epidemiol., 9, 99–106.
   PubMedGoogle Scholar
• Longo-Mbenza, B., Luila, E. L., Mbette, P. and Vita, E. K. (1999). Is hyperuricemia a risk factor of stroke and coronary heart disease among Africans? Int. J. Cardiol., 30, 17–22.
   Google Scholar
• Liese, A. D., Hense, H. W., Lowel, H., Doring, A., Tietze, M. and Keil, U. (1999). Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring trends and Determinants in Cardiovascular diseases. Epidemiology, 10, 391–397.
   PubMed Web of Science ®Google Scholar
• Emmerson, B. T. (1979). Atherosclerosis and urate metabolism. Aust. N. Z. J. Med., 9, 451–454.
   PubMedGoogle Scholar
• Ginsberg, M. H., Kozin, F., O'Malley, M. and McCarty, D. J. (1977). Release of platelet constituents by monosodium urate crystals. J. Clin. Invest., 60, 999–1007.
   PubMed Web of Science ®Google Scholar
• Frolich, E. D. (1993). Uric acid. A risk for coronary heart disease. J. Am. Med. Assoc., 270, 378–379.
   Web of Science ®Google Scholar
• Lee, J., Sparrow, D., Vokonas, P. S., Landsberg, L. and Weiss, S. T. (1995). Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome. The Normative Aging Study. Am. J. Epidemiol., 142, 288–294.
   PubMed Web of Science ®Google Scholar
• Cappuccio, R P., Strazzullo, P., Farinaro, E. and Trevisan, M. (1993). Uric acid metabolism and tubular sodium handling. Results from a population-based study. J. Am. Med. Assoc., 270, 354–359.
   PubMed Web of Science ®Google Scholar
• Ames, B. N., Cathcart, R., Schwiers, E. and Hochstein, P. (1981). Uric acid provides an antioxidant defense in humans against oxidant-, and radical-caused aging and cancer: a hypothesis. Proc. Natl. Acad. Sci. USA, 78, 6858–6862.
   PubMed Web of Science ®Google Scholar
• Sevanian, A., Davies, K. J. and Hochstein, P. (1991). Serum urate as an antioxidant for ascorbic acid. Am. J. Clin. Nutr., 54, 1129–1134.
   PubMed Web of Science ®Google Scholar
• Navab, M., Berliner, J.A., Watson, A. D., Hama, S. Y., Territo, M. C., Lusis, A. J., Shih, D. M., Van Lenten, B. J., Frank, J. S., Demer, L.L., Edwards, P. A. and Fogelman, A. M. (1996). The yin and yang of oxidation in the development of the fatty streak: a review based on the George Lyman Duff Memorial Lecture. Arterioscler. Thromb. Vasc. Biol., 16, 831–842.
   PubMed Web of Science ®Google Scholar
• Milionis, H. J., Elisaf, M. S. and Mikhailidis, D. P. (2000). Treatment of dyslipidaemias in patients with established vascular disease: a revival of the fibrates. Curr. Med. Res. Opin., 16, 21–23.
   PubMed Web of Science ®Google Scholar
• Bastow, M. D., Durrington, P. N. and Ishola, M. (1988). Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism, 37, 217–220.
   PubMed Web of Science ®Google Scholar
• Liamis, G., Bairaktari, E. T. and Elisaf, M. S. (1999). Effect of fenofibrate on serum uric acid levels. Am. J. Kidney Dis., 34, 594.
   PubMed Web of Science ®Google Scholar
• Milionis, H. J., Elisaf, M. S. and Mikhailidis, D. P. (1999). Platelet function and lipid-lowering interventions. Platelets, 10, 357–367.
   PubMed Web of Science ®Google Scholar
• Randle, P. J., Garland, P. B., Hales, C. N. and Newsholme, E. A. (1963). The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet, 1, 785–789.
   PubMed Web of Science ®Google Scholar
• Mikhailidis, D. P., Ganotakis, E. S., Spyropoulos, K. A., Jagroop, I. A., Byrne, D. J. and Winder, A. F. (1998). Pro-thrombotic and lipoprotein variables in patients attending cardiovascular risk management clinic: response to ciprofibrate and lifestyle advice. Int. Angiol., 17, 225–233.
   PubMed Web of Science ®Google Scholar
• Cappuccio, R P., Iacone, R. and Strazzullo, P. (1991). Serum uric acid and proximal sodium excretion: an independent association in man (the Olivetti study). J. Hypertens., 9(Suppl 6), S280–S281.
   Google Scholar